Navigation Links
Orchid Cellmark to Announce Fourth Quarter and Year-End 2008 Financial Results on March 16, 2009
Date:3/6/2009

PRINCETON, N.J., March 6 /PRNewswire-FirstCall/ -- Orchid Cellmark Inc. (Nasdaq: ORCH), a leading worldwide provider of identity DNA testing services, will release its fourth quarter and year-end 2008 financial results on Monday, March 16, 2009 at approximately 7:00 a.m. EDT, and is hosting a conference call and webcast to discuss the results at 10:00 a.m. EDT on the same day. Management will discuss financial results for the 2008 fourth quarter and year-end results as well as operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the live or archived webcast.

    Conference Call Details

    Date and Time:   Monday, March 16, 2009 at 10:00 a.m. EDT

    Dial-In:         US/Canada:      (877) 266-0703
                     Int'l/Local:    (706) 643-7682
                     Conference ID:  88572934

Webcast: Live webcast and replay available via the Investor Relations section of the company's website at www.orchidcellmark.com. The webcast will be available for 90 days.

About Orchid Cellmark

Orchid Cellmark (Nasdaq: ORCH) is a leading international provider of DNA testing services primarily for forensic and family relationship applications. Orchid Cellmark is one of the largest providers of forensic DNA testing services and its DNA results are used by the criminal justice system to assist with the identification of perpetrators, the exclusion of suspects and the exoneration of wrongfully convicted individuals. The company provides DNA family relationship testing to numerous child services organizations and individuals seeking to verify parentage. Orchid Cellmark also serves immigration and security authorities for DNA testing of individuals. In the agriculture field, the company provides DNA testing services for selective trait breeding. Orchid Cellmark's strong market positions in these areas reflect the company's accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the company's reputation for exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at www.orchidcellmark.com.

All statements in this press release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, risks and uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid Cellmark's products and services, dependence on government funding and collaborations, regulatory approvals, competition, intellectual property of others, patent protection, litigation, the timing of release of federal funds, the timing and amount of contracts put up for bid, and Orchid Cellmark's ability to successfully offer its services directly to U.K. police forces. These risks and other additional factors affecting these forward-looking statements and Orchid Cellmark's business are discussed under the headings "Risks Related to Our Business" and "Risks Associated with Our Common Stock" in Orchid Cellmark's Annual Report on Form 10-K for the year ended December 31, 2007, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Securities and Exchange Commission from time to time. Orchid Cellmark expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid Cellmark's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.


'/>"/>
SOURCE Orchid Cellmark Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Orchid Cellmark Reports Third Quarter 2008 Financial Results
2. Orchid Cellmark Reports Second Quarter 2008 Financial Results
3. Orchid Cellmark To Announce Second Quarter 2008 Financial Results on July 31, 2008
4. Orchid Cellmark Reports First Quarter 2008 Financial Results
5. Orchid Cellmark to Open a New Forensic Facility in the United Kingdom to Meet Increasing Demand for Its Services
6. Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results
7. Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
8. Orchid Cellmark Appoints William J. Thomas Vice President and General Counsel
9. Orchid Cellmark Reports Third Quarter 2007 Financial Results
10. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
11. Gaiam to Announce Fourth Quarter 2008 and Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... del Rey, CA (PRWEB) , ... August 22, ... ... of revenue cycle management (RCM) solutions, announced recently the availability of a new ... HIM community in appreciation for their service to the healthcare industry. E/M coding ...
(Date:8/22/2017)... ... ... Five Star Glass is new to the Texas market, but is proudly managed by widely ... makes and models, in Grand Prairie, TX, located in the center of the DFW Metroplex, ... owned business for the past 40 years with 32 convenient locations in Texas, Nevada and ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Wilderness Voices”: a collection of ... “Wilderness Voices” is the creation of published author, Martha McKown, an ordained United ... inspired as a very young child when her older sisters studied High School literature. ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Covert Awakening”: Walid’s ... of published author, Julianne Hale, a consultant for the Intelligence Community. For ... focusing on the Near East region. Julianne has written hundreds of reports ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... is the Founder and Managing Member for t4 Leadership Development & Consulting. He ... to his definition of “success”: physician leadership development, servant leadership, data driven process ...
Breaking Medicine News(10 mins):
(Date:8/11/2017)... Aug. 11, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... and big data solutions, today announced that it will ... 14 and host a conference call at 9:00am ET. ... and financial results and its strategy and outlook for ... by Erez Raphael , Chief Executive Officer, and ...
(Date:8/8/2017)... Aug. 8, 2017   ... diluted (GAAP) loss per share from continuing operations ... revenues increased 16 percent to $110 million ... 27 percent to $161 million ... from continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... FLINT, Mich. , Aug. 7, 2017 Diplomat ... appointment of Joel Saban as president, effective Aug. ... Paul Urick has decided to pursue other interests and ... period. "During his tenure, Paul has served us in multiple ... Burman,s Specialty Pharmacy in Jun. 2015 and has provided decisive, ...
Breaking Medicine Technology: